Trial Profile
Randomized Double Blind Placebo Controlled Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose LMWH Versus Placebo
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Dalteparin sodium (Primary)
- Indications Deep vein thrombosis; Vaso-occlusive crisis
- Focus Pharmacodynamics
- 15 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Jun 2014 Planned End Date changed from 1 Sep 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.
- 12 Aug 2013 Planned end date changed from 1 Dec 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.